



This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour(s) of external CME credit(s). Each participant should claim only those hours of credit that have actually been spent in the educational activity.

EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

Organised by:
The University of Hull
Course Director:
John GF Cleland MD



EBAC ACCREDITED EDUCATIONAL PROGRAMME HELD DURING THE ESC CONGRESS 2008

Key considerations in the management of acute heart failure syndromes

CLEAR INNOVATION AT THE HEART OF CARDIOLOGY

Tuesday 2 September 2008
Messe München
Zone A1, Oslo Room

Programme Chairs

John Cleland MD
Professor of Cardiology
The University of Hull
Kingston upon Hull, UK

Alexandre Mebazaa MD PhD
Professor of Medicine
University Paris 7
Paris, France

Faculty

Stefan D Anker MD PhD
Professor of Cardiology,
Charité, Campus Virchow-Klinikum
Berlin, Germany

Faiez Zannad MD PhD
Professor of Therapeutics and
Cardiology Director, Clinical
Investigation Center INSERM,
CHU and University Henri Poincaré
Nancy, France

Aldo Maggioni MD
Director, ANMCO Research Center
Florence, Italy



Otsuka Pharmaceutical Europe Ltd.

Supported by an unrestricted educational grant from Otsuka Pharmaceutical Europe Ltd. In compliance with EBAC/EACCME guidelines, all speakers/Chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

Outline

Despite advances in pharmacologic therapies for the treatment of heart failure (HF), it remains a serious and rising healthcare burden. HF is estimated to affect 1-2% of the population and accounts for nearly 40% of hospital admissions and 1-2% of healthcare expenditures in Europe. Acute heart failure syndromes (AHFS) represent a cluster of conditions with differential clinical, haemodynamic and outcome profiles not yet clearly identified. A worsening of HF symptoms is the most common presentation of AHFS and is the primary reason for hospitalisation of HF patients. Maintaining fluid and electrolyte balance in these patients is a challenge that many physicians and healthcare providers encounter. However, there is little clinical evidence on safe and effective management strategies for episodes of AHFS, not least in those that involve hyponatraemia.

In this symposium, the expert faculty will review the pathophysiology of AHFS and explain the importance of short-term symptom control combined with stabilisation of the haemodynamic condition. Furthermore, key aspects of the different approaches to AHFS management across Europe will be highlighted and current and future options for fluid management discussed.

Programme attendees will learn key aspects of the early recognition and management of AHFS including the clinical application of current and novel methods for fluid management in this vulnerable patient population.

Agenda

16:30 – 16:35

Welcome and Introductions
Alexandre Mebazaa, Co-Chair

16:35 – 16:55

Co-morbidities and their role in the onset of acute decompensation in heart failure patients
Stefan D Anker

16:55 – 17:15

Clinically relevant endpoints in acute heart failure trials
Faiez Zannad

17:15 – 17:35

Optimal fluid management in acute heart failure syndromes
Aldo Maggioni

17:35 – 17:50

The role of vasopressin in volume homeostasis and the progression of acute heart failure syndromes
John Cleland

17:50 – 18:00

Questions and answers
Co-chairs and faculty